Vertex Pharmaceuticals (NASDAQ:VRTX) Q3 results:
Revenues: $949.8M (+21.1%); product sales: $949.8M (+21.4%).
Key product sales: Kalydeco: $249M (+0.8%); Orkambi: $297 (+5.3%); Symdeko/Symkevi: $404M (+58.4%).
Net income: $57.5M (-55.3%); non-GAAP net income: $321.5M (+14.0%); EPS: $0.22 (-56.9%); non-GAAP EPS: $1.23 (+12.8%).
2019 guidance: Product sales: $3.70B – 3.75B (unch).
Shares down 2% after hours.
Previously: Vertex Pharmaceuticals EPS beats by $0.07, beats on revenue (Oct. 30)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.